Concurrent Product Co-Creation through Collaborative Networks among Pharmaceutical Manufacturing Enterprises

Basil Kusi, Cai Li, Richard Sarfo Gyasi, Jerry Mireku Afful


Collaborative Network (CN) has been the current clustering technology that embraces single and small firms to become large, vertical and horizontal enterprises for a decade now. This was predicted just after the formulation of the Electronic Market Hypothesis (EMH) which is popularly known as world-wide web (www) that businesses with common strategic goals will work closely together virtually. This is what is today known as the business-to-business (B2B). Organizations and enterprises are now taking the advantage of collaboration platforms to operate innovatively for competitive advantages and huge market shares in both local and international markets. This paper reviews the recent empirical studies on CNs as applied in the pharmaceutical industry. This review therefore revisits the core debates on CNs, its evolution, antecedents, prospects and challenges in collaboration. It ends by outlining prerequisite conditions of effective deployment of CN among pharmaceutical enterprises. There is an identification of Research and Developments (R&D) intermission in the pharmaceutical industry concerning concurrent engineering which should take place at the Pharma-biotech sector in the industry where R&D is carried out. It is now in a discovery that, Collaborative Networked Organizations (CNOs) use their virtual co-innovation platforms to support their R&D projects for rapid and simultaneous service-product innovations.

Full Text:



  • There are currently no refbacks.